Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

VentriPoint Diagnostics Ltd V.VPT

Alternate Symbol(s):  VPTDF

Ventripoint Diagnostics Ltd. is a Canada-based medical device company. It is engaged in the development and commercialization of diagnostic tools to monitor patients with heart disease. It develops a suite of applications for all heart diseases and imaging modalities, including congenital heart disease, pregnancy, pulmonary hypertension, COVID-19, technically difficult imaging and cardiotoxicity in oncology patients. It provides application of artificial intelligence to echocardiography. Its flagship product, Ventripoint Medical System (VMS+), enhances echocardiography to deliver cMRI levels of accuracy for volumetric measurements and ejection fractions for all four chambers of the heart. It has developed a solution that transforms cardiac care through its 3D ECHO and MRI software. VMS products are powered by its proprietary Knowledge Based Reconstruction technology, which is the result of a decade of development and provides accurate volumetric cardiac measurements equivalent to MRI.


TSXV:VPT - Post by User

Comment by Pandoraon Apr 04, 2024 4:49pm
105 Views
Post# 35971360

RE:RE:RE:Conference call

RE:RE:RE:Conference call
G1945V wrote:
WalkOverTheStrt wrote: I've personally spoken to Hugh (3 weeks ago) and came away impressed.   He in 6 weeks has ramped up incredibly quickly and accomplished some decent early wins/steps. I believe he has the right vision and sales-brand- marketing strategy to get sales ramped. I wasn't impressed with GA or Alvira if that gives any context. I expect 2024 to slowly proceed with some potential wild cards to help drive the stock price but am conservatively looking at 2025 for the real movements. 


Isn't  Hugh an interim CEO?


G1945V



Toronto, Ontario – February 13, 2024 - Ventripoint Diagnostics Ltd. ("Ventripoint" or the "Company"), (TSXV:VPT)(OTCVPTDF) announces changes to the Board of Directors.

With the recent appointment of Hugh MacNaught as Interim CEO and President, the composition of board committees has been adjusted as follows:.

Nominating and Corporate Governance Committee: Dr. George Adams (chair), Robert Hodgkinson, Hugh MacNaught

Compensation Committee: Fiona Fitzgerald, Randy Aucoin

Audit Committee: Robert Hodgkinson (chair), Randy AuCoin, George Adams,

Further, Dr. Alvira Macanovic has resigned as a director of the Company effective February 12, 2024.
<< Previous
Bullboard Posts
Next >>